Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Movymia

- PMLiVE

Merck gets US green light for allergy immunotherapy

Expected to provide a significant boost to company's partner Alk-Abello

- PMLiVE

Oral hepatitis C regimens tackle advanced liver disease

 New data released at the International Liver Congress by AbbVie, Merck & Co and Gilead

- PMLiVE

EMA to carry out four safety reviews

And recommends against combination of medicines affecting RAS system in latest PRAC highlights

- PMLiVE

Herceptin could face biosimilars in UK later this year

Court overturns patents protecting Roche’s cancer drug

- PMLiVE

EU and Australian regulators collaborate on rare diseases

EMA and Therapeutic Goods Administration to share reports for orphan drugs

- PMLiVE

AbbVie drops legal case against EMA

Accepts publication of new set of redacted Humira data

- PMLiVE

Doctors criticise FDA over Lemtrada rejection

Say Sanofi/Genzyme’s MS drug should have been approved

- PMLiVE

Sanofi appoints ‘chief patient officer’

Dr Anne Beal will lead pharma company’s efforts to improve its focus on patients

- PMLiVE

EMA’s Dr Stella Blackburn joins Quintiles

Takes up global head of risk management post

- PMLiVE

GSK withdraws melanoma combo in EU

EMA says it needs more data to review Mekinist and Tafinlar

- PMLiVE

NICE refuses to back Zaltrap as Sanofi exhausts its options

Patient access scheme and appeal fail to overcome cost concerns

- PMLiVE

EMA backs Janssen rare disease drug for approval

Castleman's disease treatment Sylvant wins CHMP recommendation

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links